Letter: Increased Rate of Ocular Disease Following Atopic Dermatitis Treatment with Dupilumab: An International Retrospective Study.

Dupixent (dupilumab) - Sanofi, Regeneron

Letter: Increased Rate of Ocular Disease Following Atopic Dermatitis Treatment with Dupilumab: An International Retrospective Study. (PubMed, Dermatitis) - Oct 25, 2026 - No abstract available
Journal • Retrospective data • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Ophthalmology

http://www.ncbi.nlm.nih.gov/pubmed/42914574

Amritpal Kooner; Mihir Kumar; Peter Lio; Selina J Chang; Sophia Manduca

Oct 25, 2026